Liver-specific expression of p53-negative regulator mdm2 leads to growth retardation and fragile liver in zebrafish

Developmental Dynamics

Volumn 237, Issue 4, 2008, Pages 1070-1081

  Chen, Li Je ^a   Hsu, Chia Chun ^b   Hong, Jiann Ruey ^c   Jou, Luen Kuang ^a   Tseng, Hung Chia ^d   Wu, Jen Leih ^e   Liou, Yih Cherng ^f   Her, Guor Mour ^a  

^a NATIONAL TAIWAN OCEAN UNIVERSITY   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN NORMAL UNIVERSITY   (Taiwan)

^e INSTITUTE OF CELLULAR AND ORGANISMIC BIOLOGY   (Taiwan)

^f NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Agenesis, atrophy; Contraction; GFP; Hepatogenesis; Hypoplasia; Liver degeneration; Mdm2; p53

Indexed keywords

GREEN FLUORESCENT PROTEIN; HYBRID PROTEIN; PROTEIN MDM2;

ANIMAL TISSUE; ARTICLE; EMBRYO; GENE OVEREXPRESSION; GROWTH RETARDATION; LARVAL DEVELOPMENT; LETHALITY; LIVER ATROPHY; LIVER DEVELOPMENT; LIVER DISEASE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE SPECIFICITY; TRANSGENIC ANIMAL; WILD TYPE; ZEBRA FISH;

AMINO ACID SEQUENCE; ANIMALS; ANIMALS, GENETICALLY MODIFIED; CELL CYCLE; CELL DEATH; CELL PROLIFERATION; GENE EXPRESSION REGULATION, DEVELOPMENTAL; HUMANS; LIVER; MOLECULAR SEQUENCE DATA; MORPHOGENESIS; PHENOTYPE; PROTO-ONCOGENE PROTEINS C-MDM2; RECOMBINANT FUSION PROTEINS; SEQUENCE ALIGNMENT; TUMOR SUPPRESSOR PROTEIN P53; ZEBRAFISH; ZEBRAFISH PROTEINS;

DANIO RERIO;

EID: 42149116970     PISSN: 10588388     EISSN: 10970177     Source Type: Journal    
DOI: 10.1002/dvdy.21477     Document Type: Article

References (42)

1. Berghmans S, Murphey RD, Wienholds E, Neuberg D, Kutok JL, Fletcher CD, Morris JP, Liu TX, Schulte-Merker S, Kanki JP, Plasterk R, Zon LI, Look AT. 2005. Tp53 mutant zebrafish develop malignant peripheral nerve sheath tumors. Proc Natl Acad Sci USA 102:407-412.
2. Bessard AC, Garay E, Lacronique V, Legros Y, Demarquay C, Houque A, Portefaix JM, Granier C, Soussi T. 1998. Regulation of the specific DNA binding activity of Xenopus laevis p53: Evidence for conserved regulation through the carboxy-terminus of the protein. Oncogene 16:883-890.
3. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang SJ, Strong LC, Lozano G, Levine AJ. 2004. A single nucleotide polymorphism in the mdm2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119:591-602.
4. Bond GL, Hirshfield KM, Kirchhoff T, Alexe G, Bond EE, Robins H, Bartel F, Taubert H, Wuerl P, Hait W, Toppmeyer D, Offit K, Levine AJ. 2006. Mdm2 snp309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res 66:5104-5110.
5. Brooks CL, Gu W. 2004. Dynamics in the p53-mdm2 ubiquitination pathway. Cell Cycle 3:895-899.
6. Chen J, Ruan H, Ng SM, Gao C, Soo HM, Wu W, Zhang Z, Wen Z, Lane DP, Peng J. 2005. Loss of function of def selectively up-regulates delta113p53 expression to arrest expansion growth of digestive organs in zebrafish. Genes Dev 19:2900-2911.
7. Cho YH, Murakami G, Lee MS, Song CH, Han EH, Jin ZW, Cho BH. 2003. Hypoplasia of the left portal vein territory of the human liver: A case study. J Korean Med Sci 18:828-832.
8. Corcoran CA, Huang Y, Sheikh MS. 2004. The p53 paddy wagon: Cop1, pirh2 and mdm2 are found resisting apoptosis and growth arrest. Cancer Biol Ther 3:721-725.
9. Dang J, Kuo ML, Eischen CM, Stepanova L, Sherr CJ, Roussel MF. 2002. The ring domain of mdm2 can inhibit cell proliferation. Cancer Res 62:1222-1230.
10. Drummond IA. 2005. Kidney development and disease in the zebrafish. J Am Soc Nephrol 16:299-304.
11. Folberg-Blum A, Sapir A, Shilo BZ, Oren M. 2002. Overexpression of mouse mdm2 induces developmental phenotypes in Drosophila. Oncogene 21:2413-2417.
12. Ganguli G, Wasylyk B. 2003. P53-independent functions of mdm2. Mol Cancer Res 1:1027-1035.
13. Giono LE, Manfredi JJ. 2006. The p53 tumor suppressor participates in multiple cell cycle checkpoints. J Cell Physiol 209:13-20.
14. Giono LE, Manfredi JJ. 2007. Mdm2 is required for inhibition of cdk2 activity by p21, thereby contributing to p53-dependent cell cycle arrest. Mol Cell Biol 27:4166-4178.
15. Goessling W, North TE, Zon LI. 2007. New waves of discovery: Modeling cancer in zebrafish. J Clin Oncol 25:2473-2479.
16. Haramis AP, Hurlstone A, van der Velden Y, Begthel H, van den Born M, Offerhaus GJ, Clevers HC. 2006. Adenomatous polyposis coli-deficient zebrafish are susceptible to digestive tract neoplasia. EMBO Rep 7:444-449.
17. Helton ES, Chen X. 2007. P53 modulation of the DNA damage response. J Cell Biochem 100:883-896.
18. Her GM, Chiang CC, Chen WY, Wu JL. 2003a. In vivo studies of liver-type fatty acid binding protein (1-fabp) gene expression in liver of transgenic zebrafish (Danio rerio). FEBS Lett 538:125-133.
19. Her GM, Yeh YH, Wu JL. 2003b. 435-bp liver regulatory sequence in the liver fatty acid binding protein (1-fabp) gene is sufficient to modulate liver regional expression in transgenic zebrafish. Dev Dyn 227:347-356.
20. Her GM, Cheng CH, Hong JR, Sundaram GS, Wu JL. 2006. Imbalance in liver homeostasis leading to hyperplasia by overexpressing either one of the bcl-2-related genes, zfblp1 and zfmcl-1a. Dev Dyn 235:515-523.
21. Hirata H, Watanabe T, Hatakeyama J, Sprague SM, Saint-Amant L, Nagashima A, Cui WW, Zhou W, Kuwada JY. 2007. Zebrafish relatively relaxed mutants have a ryanodine receptor defect, show slow swimming and provide a model of multi-minicore disease. Development 134:2771-2781.
22. Hostetter CL, Sullivan-Brown JL, Burdine RD. 2003. Zebrafish pronephros: A model for understanding cystic kidney disease. Dev Dyn 228:514-522.
23. Ito A, Kawaguchi Y, Lai CH, Kovacs JJ, Higashimoto Y, Appella E, Yao TP. 2002. Mdm2-hdac1-mediated deacetylation of p53 is required for its degradation. Embo J 21:6236-6245.
24. Jin Y, Lee H, Zeng SX, Dai MS, Lu H. 2003. Mdm2 promotes p21waf1/cip1 proteasomal turnover independently of ubiquitylation. EMBO J 22:6365-6377.
25. Jones SN, Roe AE, Donehower LA, Bradley A. 1995. Rescue of embryonic lethality in mdm2-deficient mice by absence of p53. Nature 378:206-208.
26. Jones SN, Hancock AR, Vogel H, Donehower LA, Bradley A. 1998. Overexpression of mdm2 in mice reveals a p53-independent role for mdm2 in tumorigenesis. Proc Natl Acad Sci USA 95:15608-15612.
27. Langheinrich U, Hennen E, Stott G, Vacun G. 2002. Zebrafish as a model organism for the identification and characterization of drugs and genes affecting p53 signaling. Curr Biol 12:2023-2028.
28. Lee UY, Murakami G, Han SH. 2004. Left lobe hypoplasia of the human liver: A report of two cases. Surg Radiol Anat 26:417-423.
29. Lieschke GJ, Currie PD. 2007. Animal models of human disease: Zebrafish swim into view. Nat Rev Genet 8:353-367.
30. Lu WJ, Abrams JM. 2006. Lessons from p53 in non-mammalian models. Cell Death Differ 13:909-912.
31. Lundgren K, Montes de Oca Luna R, McNeill YB, Emerick EP, Spencer B, Barfield CR, Lozano G, Rosenberg MP, Finlay CA. 1997. Targeted expression of mdm2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53. Genes Dev 11:714-725.
32. Marechal V, Elenbaas B, Taneyhill L, Piette J, Mechali M, Nicolas JC, Levine AJ, Moreau J. 1997. Conservation of structural domains and biochemical activities of the mdm2 protein from Xenopus laevis. Oncogene 14:1427-1433.
33. May P, May E. 1999. Twenty years of p53 research: Structural and functional aspects of the p53 protein. Oncogene 18:7621-7636.
34. Morrison RS, Kinoshita Y, Johnson MD, Guo W, Garden GA. 2003. P53-dependent cell death signaling in neurons. Neurochem Res 28:15-27.
35. Ohkubo S, Tanaka T, Taya Y, Kitazato K, Prives C. 2006. Excess hdm2 impacts cell cycle and apoptosis and has a selective effect on p53-dependent transcription. J Biol Chem 281:16943-16950.
36. Shmueli A, Oren M. 2007. Mdm2: P53's lifesaver? Mol Cell 25:794-796.
37. Thisse C, Neel H, Thisse B, Daujat S, Piette J. 2000. The mdm2 gene of zebrafish (Danio rerio): Preferential expression during development of neural and muscular tissues, and absence of tumor formation after overexpression of its cdna during early embryogenesis. Differentiation 66:61-70.
38. Toledo F, Wahl GM. 2006. Regulating the p53 pathway: In vitro hypotheses, in vivo Veritas. Nat Rev Cancer 6:909-923.
39. Wahl G, Vafa O. 2000. Genetic instability, oncogenes, and the p53 pathway. Cold Spring Harb Symp Quant Biol 65:511-520.
40. Wallingford JB, Seufert DW, Virta VC, Vize PD. 1997. P53 activity is essential for normal development in Xenopus. Curr Biol 7:747-757.
41. Yang Y, Li CC, Weissman AM. 2004. Regulating the p53 system through ubiquitination. Oncogene 23:2096-2106.
42. Zhang Z, Wang H, Li M, Agrawal S, Chen X, Zhang R. 2004. Mdm2 is a negative regulator of p21waf1/cip1, independent of p53. J Biol Chem 279:16000-16006.